1. Home
  2. BWXT vs MDGL Comparison

BWXT vs MDGL Comparison

Compare BWXT & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BWX Technologies Inc.

BWXT

BWX Technologies Inc.

HOLD

Current Price

$137.71

Market Cap

12.3B

Sector

N/A

ML Signal

HOLD

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$429.21

Market Cap

11.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWXT
MDGL
Founded
1867
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3B
11.5B
IPO Year
2010
2005

Fundamental Metrics

Financial Performance
Metric
BWXT
MDGL
Price
$137.71
$429.21
Analyst Decision
Buy
Strong Buy
Analyst Count
18
19
Target Price
$209.44
★ $685.22
AVG Volume (30 Days)
★ 1.1M
273.9K
Earning Date
11-02-2026
11-03-2026
Dividend Yield
★ 0.80%
N/A
EPS Growth
★ 16.61
N/A
EPS
★ 0.99
N/A
Revenue
★ $1,687,738,000.00
$180,133,000.00
Revenue This Year
$19.30
$59.43
Revenue Next Year
$9.35
$38.83
P/E Ratio
$136.33
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$123.05
$399.00
52 Week High
$241.82
$615.00

Technical Indicators

Market Signals
Indicator
BWXT
MDGL
Relative Strength Index (RSI) 48.52 29.53
Support Level $133.21 $416.21
Resistance Level $147.00 $546.29
Average True Range (ATR) 4.62 16.26
MACD 0.66 -1.31
Stochastic Oscillator 67.82 10.31

Price Performance

Historical Comparison
BWXT
MDGL

About BWXT BWX Technologies Inc.

BWX Technologies Inc is a specialty manufacturer and service provider of nuclear components, operating in two segments: Government Operations and Commercial Operations. The Government Operations segment produces naval nuclear reactors and fuel for the U.S. Naval Nuclear Propulsion Program, while the Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, reactor components, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level nuclear waste. The majority of the company's revenue comes from Government Operations, with sales principally in the United States, Canada, and other regions.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Share on Social Networks: